Press release from Companies

Published: 2022-06-23 08:54:16

WntResearch AB: 120 patients recruited for the ongoing Phase 2 study NeoFox

As a total of 120 patients have been recruited for the ongoing phase 2 study NeoFox, the next goal is to study available data in the upcoming interim analysis in December.

The purpose of the interim analysis in the NeoFox study is to provide indicative data on Foxy-5's potential for preventing disease recurrence and thereby guide the company in how many patients needed to be recruited in achieving the primary goal. The analysis will also show that the study in general can continue as planned.

“It is very satisfying in reaching 120 recruited patients and we look forward to conducting the interim analysis in December. In light of the interim analysis, we will make an overall strategic decision on how we will proceed with the NeoFox study”, says CEO Pernilla Sandwall.

For further information:

Pernilla Sandwall, CEO WntResearch AB

About WntResearch

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumor cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.

WntResearch is listed on the Spotlight Stock Market. For more information, please visit:

Follow WntResearch on linked in

Läs mer hos Cision
Read more about WntResearch AB